SCHEMBL1677244

SCHEMBL1677244

c1coc(-c2csc(-c3nc4cnccc4[nH]3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.56
▸ HSD17B10 Q99714 5/20 0.56
▸ ALDH1A1 P00352 5/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ HPGD P15428 3/20 0.56
▸ KMT2A Q03164 3/20 0.56
▸ ALOX15 P16050 3/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ CYP19A1 P11511 2/20 0.51
▸ KDM4E B2RXH2 5/20 0.49
▸ RAB9A P51151 4/20 0.49
▸ PKM P14618 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ KDM4C Q9H3R0 1/20 0.49
▸ TP53 P04637 3/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ BRCA1 P38398 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1677820 0.85 HSD17B10 (0.67) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL1677344 0.77 CYP19A1 (0.59) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL7253210 0.72 CYP19A1 (0.72) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL11228706 0.70 ALDH1A1 (0.68) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL1677420 0.69 CYP19A1 (0.49) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL10376423 0.69 KDM4E (0.67) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL1678585 0.67 CYP19A1 (0.46) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL28572420 0.66 ALDH1A1 (0.47) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL29545885 0.65 CHEK1 (0.72) MAPTALDH1A1SMN1; SMN2HPGDKMT2A
SCHEMBL7965438 0.65 KDM4E (1.00) MAPTHSD17B10ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921077-B1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KIRIN CO LTD (JP) 2017-07-26 — — EP disclosed
US-7928098-B2 Therapeutic and/or preventive agents for a sleep disorder KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-19 — — US disclosed
US-20100280023-A1 THIAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2010-11-04 — — US disclosed
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-06-17 — — US disclosed
EP-1921077-A1 AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-14 — — EP disclosed
EP-1894930-A1 THIAZOLE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152162-A1 THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER HCRTR1, MTNR1A, HCRTR2 MAPT 2204/4885HSD17B10 125/4885ALDH1A1 638/4885
US-20100280023-A1 THIAZOLE DERIVATIVES ADORA2A, ADORA3, GPR6 MAPT 3668/4885HSD17B10 1946/4885ALDH1A1 1449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback